Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece

ANN ARBOR, MI / ACCESSWIRE / January 4, 2024 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in canine patients without sedation.

The article, titled “Use of a novel shockwave trode results in better patient acceptance in awake canine patients treated for musculoskeletal disease” was published in Frontiers in Veterinary Science and written by Dr. Gina L. Joseph and team at Colorado State University (CSU, Ft Collins, CO), and is available here: https://www.frontiersin.org/articles/10.3389/fvets.2023.1249592/full.

In addition to this publication, CSU is currently evaluating the effectiveness of PulseVet therapy for slowing the progression of canine osteoarthritis. Enrollment for this study has been completed and initial results are expected later in 2024.

Current clinical evidence shows that electro-hydraulic shock wave therapy is effective for multiple indications such as tendon and ligament healing, bone healing, alleviation of chronic back pain, osteoarthritis, and wound healing. The ability to treat these patients without sedation using X-Trode could enable many more patients to receive the benefits of this therapy.

Dr. Felix Duerr, Professor of Small Animal Orthopedic Medicine at CSU, and a co-author of the article, stated, “we are excited about our partnership with Zomedica and truly appreciate their enthusiastic support of research to validate this modality. This first study verifies that the treatment is well-tolerated, and we are eagerly anticipating the results of the osteoarthritis study.”

Dr. Jennifer Vitucci, Professional Services Veterinarian for Therapeutics at Zomedica stated, “there is substantial evidence that electro-hydraulic shock wave therapy is clinically effective for many indications such as tendon and ligament healing, bone healing, alleviation of chronic back pain, osteoarthritis, and wound healing. The ability to treat these patients without sedation using X-Trode could enable many more patients to receive the benefits of this therapy.”

“There are several significantly different types of shock wave generators available for veterinary applications. Historically, electro-hydraulic generators have shown the most evidence in terms of efficacy but have been challenged in terms of acceptance by the need for sedation to complete treatments. With the X-Trode we are able to spread the shock wave energy over a larger volume of tissue and reduce the peak level of focused energy, thereby reducing the potential for pain associated with the treatment while still delivering a clinically effective amount of energy to the treatment area. CSU’s first study verifies that the treatment is well-tolerated. We are excited for the results of their upcoming study to further validate the efficacy of PulseVet electro-hydraulic shock wave therapy,” stated Adrian Lock, Vice President of Clinical and Veterinary Affairs at Zomedica.

Larry Heaton, Zomedica CEO stated, “PulseVet shock wave therapy has long been a standard of care treatment modality for many equine indications. Acceptance for this therapy is now gaining substantial traction for small animal patients and this publication should accelerate that momentum building while further advancing the science of shock wave therapy and specifically differentiating shock wave generator types in terms of capability and patient benefit.”

PulseVet’s shock wave therapy harnesses high-energy sound waves to stimulate cells and promote the release of healing growth factors within the body which have been shown to modulate inflammation, enhance blood flow, increase bone density, and accelerate healing.

Zomedica remains steadfast in its commitment to staying at the forefront of non-invasive, regenerative options in veterinary care. It’s unwavering dedication to advancing veterinary care is demonstrated through its ongoing clinical studies, which have yielded promising results in various shock wave areas.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://m.facebook.com/zomedica
• Twitter: https://twitter.com/zomedica
• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor

Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on accesswire.com